The Supplementation Therapy in Autism and Response to Treatment Study

NARecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 1, 2023

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2026

Conditions
AutismAutism Spectrum DisorderAutism Spectrum Disorder High-FunctioningAsperger SyndromeDepressive SymptomsAnxiety State
Interventions
DIETARY_SUPPLEMENT

Oral Ultramicronized-Palmitoylethanolamide (um-PEA; 600 mg per day) in tablet form

Um-PEA is to be taken orally once a day (600 mg per day) around mealtime during the 12-week initial phase of the study. During the 24-week extension phase of the study, the trial medication is to be taken from once a day up to twice a day (600-1200 mg per day), based on clinical judgment of the improvement obtained so far, around mealtime.

Trial Locations (1)

33100

RECRUITING

Unit of Psychiatry, University Hospital of Udine, Udine

All Listed Sponsors
lead

University of Udine

OTHER